Morgan Stanley analyst Patrick Wood lowered the firm’s price target on Staar Surgical (STAA) to $23 from $27 and keeps an Underweight rating on the shares. While stating that the “company is doing all the right things,” the firm think Staar is operating in a very difficult refractive market in China and the U.S. and remains cautious.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- Staar Surgical price target lowered to $31 from $41 at Canaccord
- Staar Surgical price target lowered to $49 from $53 at BTIG
- STAAR Surgical Posts Strong Q3 2024 Financial Results
- Staar Surgical Achieves 10% Sales Growth, Income Doubles
- Staar Surgical sees FY24 revenue $340M-$345M, consensus $343.56M